跳至主要内容
临床试验/IRCT20160419027479N2
IRCT20160419027479N2尚未招募1 期

Investigation of the safety of autologous immune cells injection enriched with NK (Natural killer) cells to the patients with refractory breast cancer

VC for Research and Technology and Institute for stem cells and regenerative medicine, Shiraz Unive0 个研究点目标入组 3 人开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
3

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 60 years(—)
性别
Female

入选标准

  • Patients with breast cancer, Infiltrative Ductal Carcinoma (IDC)
  • Patients with end stage breast cancer (Stage 4)
  • Patients with refractory breast cancer based on National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines
  • Triple negative (ER-,PR- and Her2-) breast cancer patients
  • Patients with the minimum age of 18 years old and maximum 60 years old
  • Performance status =0 or 1
  • Life expectancy for patients: more than 3 months

排除标准

  • Patients with autoimmune disease
  • Patients with active infection
  • Patients who spend the intensive radiotherapy
  • Pregnant patients

研究者

发起方
VC for Research and Technology and Institute for stem cells and regenerative medicine, Shiraz Unive

相似试验